3-(1,3-benzothiazol-5-yl)-7-(1,3-dimethyl-1H-pyrazol-5-yl)thieno[3,2-c]pyridin-4-amine manufacturers
- GSK-843
-
- $149.00 / 1mg
-
2024-10-28
- CAS:1601496-05-2
- Min. Order:
- Purity: 99.18%
- Supply Ability: 10g
- GSK-843
-
- $149.00 / 1mg
-
2024-10-24
- CAS:1601496-05-2
- Min. Order:
- Purity: 99.18%
- Supply Ability: 10g
|
| 3-(1,3-benzothiazol-5-yl)-7-(1,3-dimethyl-1H-pyrazol-5-yl)thieno[3,2-c]pyridin-4-amine Basic information |
Product Name: | 3-(1,3-benzothiazol-5-yl)-7-(1,3-dimethyl-1H-pyrazol-5-yl)thieno[3,2-c]pyridin-4-amine | Synonyms: | 3-(1,3-benzothiazol-5-yl)-7-(1,3-dimethyl-1H-pyrazol-5-yl)thieno[3,2-c]pyridin-4-amine;GSK-843;Thieno[3,2-c]pyridin-4-amine, 3-(5-benzothiazolyl)-7-(1,3-dimethyl-1H-pyrazol-5-yl)-;GSK843,GSK 843;GSK'843;3-(Benzo[d]thiazol-5-yl)-7-(1,3-dimethyl-1H-pyrazol-5-yl)thieno[3,2-c]pyridin-4-amine;GSK-843, 10 mM in DMSO | CAS: | 1601496-05-2 | MF: | C19H15N5S2 | MW: | 377.49 | EINECS: | | Product Categories: | | Mol File: | 1601496-05-2.mol | ![3-(1,3-benzothiazol-5-yl)-7-(1,3-dimethyl-1H-pyrazol-5-yl)thieno[3,2-c]pyridin-4-amine Structure](CAS/20180528/GIF/1601496-05-2.gif) |
| 3-(1,3-benzothiazol-5-yl)-7-(1,3-dimethyl-1H-pyrazol-5-yl)thieno[3,2-c]pyridin-4-amine Chemical Properties |
Boiling point | 640.0±55.0 °C(Predicted) | density | 1.54±0.1 g/cm3(Predicted) | storage temp. | Store at -20°C | solubility | Soluble in DMSO | form | Solid | pka | 5.62±0.40(Predicted) | color | Light yellow to yellow |
| 3-(1,3-benzothiazol-5-yl)-7-(1,3-dimethyl-1H-pyrazol-5-yl)thieno[3,2-c]pyridin-4-amine Usage And Synthesis |
Uses | GSK-843 (GSK'843) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC50 of 8.6 nM, and inhibits kinase activity with an IC50 of 6.5 nM. GSK-843 can be used for the research of inflammation[1][2]. | Biological Activity | GSKμ843 is a potent ATP-competitive RIP3 (RIPK3) kinase inhibitor (IC50 = 6.5 nM) with much reduced or little affinity toward 262 other kinases (IC50 >1 μM against 10 μM ATP in competitive binding assay), including RIP5. GSKμ843 effectively suppresses TNF/Z-VAD-FMK/IAP agonist treatment-induced necrosis induction in both human and murine cell cultures (EC50 ranges from <0.12 to 3 μM), while inducing apoptosis in the absence of caspase inhibitor as a result of caspase 8 activation via RHIM-driven recruitment to assemble a Casp8-FADD-cFLIP complex independent of pronecrotic kinase activities and MLKL. | IC 50 | RIPK3 | References | [1] Mandal P, et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell. 2014 Nov 20;56(4):481-95. DOI:10.1016/j.molcel.2014.10.021 [2] Kaiser WJ, et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem. 2013 Oct 25;288(43):31268-79. DOI:10.1074/jbc.M113.462341 |
| 3-(1,3-benzothiazol-5-yl)-7-(1,3-dimethyl-1H-pyrazol-5-yl)thieno[3,2-c]pyridin-4-amine Preparation Products And Raw materials |
|